NASDAQHealth CareHealth Information ServicesSnapshot 2026-07-23
Reading WAY? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a stable growth opportunity in the healthcare sector. The current thesis is intact, supported by strong recent financial performance and a focus on revenue growth.
The market appears to have a neutral valuation on WAY, with expectations slightly below peers. The current pricing reflects a justified position, suggesting that while the stock is not overly expensive, it is also not significantly undervalued.
Management has shown a commitment to increasing revenue and operating income, with recent results indicating progress. However, there are mixed signals regarding cash flow improvements, and the near-term risk of missing earnings remains low but present.
The long-term thesis hinges on the performance of sector bellwethers like VEEV, BTSG, and TEM. Positive earnings and guidance from these companies could support WAY, while any negative trends could pose risks to its growth trajectory.
In the next 1 to 3 years, WAY's performance will depend on its ability to sustain growth amid sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improvement, indicating that the company's financial performance remains strong. There are no current threats to the thesis.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: If it drops below 20%, growth may weaken. This could hurt investor confidence.
Confirms:Q2 revenue growth reported below 20% year over year.
Disproves:Q2 revenue growth remains above 20% year over year.
Why it matters: If it drops below 40%, there may be operational problems. This could hurt profits.
Confirms:The adjusted EBITDA margin is now below 40%.
Disproves:Adjusted EBITDA margin is at or above 40%.
Why it matters: Less cash flow may limit Waystar's ability to invest in growth.
Confirms:Cash from operations is below $80 million.
Disproves:Cash from operations remains at or above $80 million.
Why it matters: Higher operating income growth means better cost control. This shows the company is healthy.
Confirms:Operating income growth is over 15% compared to last year.
Disproves:Operating income growth is below 15% compared to last year.
Why it matters: More cash flow from operations helps Waystar invest in growth.
Confirms:Cash flow from operations exceeds $90 million in Q2.
Disproves:Cash flow from operations falls below $80 million in Q2.
Why it matters: A high adjusted EBITDA margin shows good cost control. It also shows the company runs well.
Confirms:Adjusted EBITDA margin is over 43% in Q2.
Disproves:Adjusted EBITDA margin drops below 40% in Q2.
Why it matters: Improving cash from operations is critical for Waystar's financial health. It supports growth and investments.
Confirms:Cash from operations shows a positive change compared to the previous quarter.
Disproves:Cash from operations is the same or lower than last quarter.
Why it matters: If sector growth drops, it may affect Waystar's performance. This signals broader issues.
Confirms:Health Care sector revenue growth reported below its median.
Disproves:Health Care sector revenue growth stays at or above its median.
Why it matters: If it falls below 110%, there may be problems with keeping clients and upselling.
Confirms:Net revenue retention rate is below 110%.
Disproves:Net revenue retention rate remains at or above 110%.
Why it matters: More cash flow helps support growth plans. It shows the company is strong.
Confirms:Cash from operations growth reported above 20% year over year.
Disproves:Cash from operations growth reported below 20% year over year.
